Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials-Reference-Cited by-同舟云学术

Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials

Published:2023-07 Issue:4 Volume:22 Page:652-655
ISSN:1569-1993
Container-title:Journal of Cystic Fibrosis
language:en
Short-container-title:Journal of Cystic Fibrosis

Author:

VanDevanter D.R.^ORCID,Zemanick E.T.^ORCID,Konstan M.W.^ORCID,Ren C.L.^ORCID,Odem-Davis K.^ORCID,Emerman I.,Young J.,Mayer-Hamblett N.

Funder

National Institutes of Health

Cystic Fibrosis Foundation

Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Reference10 articles.

1. CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine;Lopes-Pacheco;Front Pharmacol,2020

2. Elexacaftor-Tezacaftor-Ivacaftor: the first triple-combination cystic fibrosis transmembrane conductance regulator modulating therapy;Ridley;J Pediatr Pharmacol Ther,2020

3. When triple therapy is not working: reverse iceberg perspective;Castellani;J Cyst Fibros,2023

4. CFTR modulator drug desensitization: preserving the hope of long term improvement;Leonhardt;Pediatr Pulmonol,2021

5. How many billions is enough? Prioritizing profits over patients with cystic fibrosis;McGarry;Pediatr Pulmonol,2023

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective;The Lancet Respiratory Medicine;2023-10

2. Chronic daily respiratory care needs in people with cystic fibrosis treated with highly effective cystic fibrosis transmembrane conductance regulator modulators;Current Opinion in Pulmonary Medicine;2023-08-23